UK Markets open in 4 hrs 52 mins

Prothena Corporation plc (PRTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
35.47+0.24 (+0.68%)
At close: 04:00PM EST
35.47 0.00 (0.00%)
After hours: 04:47PM EST
Sign in to post a message.
  • J
    Jerome Powell
    It’s desd
  • H
    H
    Should have dumped it when Cramer pumped it about two months ago!
  • v
    victor
    Should drop to $33 but I will buy it back at the lower support, I'm good for waiting, otherwise, good luck to all.
  • B
    Barnacle Barney
    "Clinical stage company" is code for high risk, and sharp drops in market capitalization.
  • H
    H
    Disaster since Cramer pumped it 2 months ago! When Cramer pumps…it’s a sign to DUMP!
  • F
    Fissber
    #PRTA in play. Bullish technical indication at stoxline. Might be the start of upside move. Looking for breakout at $10. http://www.foxchart.com/share/352612621.png
  • L
    LouisM
    There was a position owned by Woodford Investment Management amounting to 8.8 million shares as of June 29,2019. Woodford was being forced to liquidate their position because investors wanted out of Woodford. It looks like EcoR1 Capital acquired Woodfords position. That relieved a huge over hang on the market which was exaserbated by low volume. Other investors were standing aside to get PRTA cheap as Woodford was forced to sell. The shorts were loving it and covering. Shares short has declined from 6 million shares a year ago to 2.2 million now. So the shore is on the other foot. Shorts will be more motivated to cover since Woodford supply has gone away.
  • m
    melanie
    Last week….Shares of Prothena (NASDAQ:PRTA) skyrocketed 55.4% after Oppenheimer increased its price target for the biotech stock to $54 on increased optimism about the prospects for the company's two preclinical Alzheimer's disease programs.
  • S
    Sram
    3:56 pm ET
    *Prothena Corp 13D Shows EcoR1 Capital Holds 23.6% Stake In Co.
    Benzinga
  • L
    La
    ER tomorrow fingers cross.
  • N
    Nino
    This company accepted the reality that their end and most important product was doomed. The company is still forging ahead. They're not done. Celgene invested millions on this company. This is the time to buy. Biotechnology companies by their very nature are working to improve one's health with new products. Sometimes these don't materialize, but they must continue. Prothena is doing just that.
  • D
    Dave
    Prothena has been advancing Birtamimab into the confirmatory Phase 3 AFFIRM-AL study in patients with AL amyloidosis categorized as Mayo Stage IV. It has been granted orphan drug designation for AL Amyloidosis by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency and has been granted Fast Track designation by the FDA.

    News on either of these drugs with such low float could send PRTA up fast and hard. It ran to $67 last week. They also have an Alzheimer’s Disease drug in Phase I studies and it pulled back when the FDA released news on BIIB.

    https://www.prothena.com/pipeline/birtamimab/
    AL Amyloidosis | Prothena
    www.prothena.com
  • G
    George
    going ALL IN, owned it at $60 made tens of thousands and thankfully not around for the 70% hammer job but company will survive and its worth a trade.
  • J
    Jim
    I lost my best friend to Amyloidosis a few years back. Sorry to see the drug fail. I hope someday soon there is a breakthrough to solve the protein puzzle.
  • I
    Inv
    Celgene as part of its recent $150 million deal. 
    On the plus side, Prothena's balance sheet held more than $421 million in cash at year end, and the Celgene investment should only add to that number. That means that the company won't need to raise capital anytime soon, which is good news given where its share price is heading today.
  • L
    LouisM
    Is there a Yahoo monitor of this conversation board? If so they are not doing their job! Below RIDE made two posts regarding Proterra (PTRA) a TOTALLY different company from this board's topic Prothena (PRTA).
    I pointed this out and the monitor has done nothing about it.
  • m
    money_insider_stocknews
    Prothena Corporation plc (PRTA), 10% Owner, Ecor Capital, LLC, Filled Form 4, on 03/24/2021, Disposed 875,000 shares, at Price $20.75 worth $18,156,250 Follow On Instagram, money_insider_stocknews
    Facebook, @Earnegy
    For Stocks Inside News and Details.
  • J
    Javy
    i wish all my stocks would behave like this one. Not a seller just happy on the ride up.
  • A
    Angela
    Anyone knows if PRTA has a patent for AD. Today AVXL someone bright the patent for AD. Something BIG coming for AVXL